1. Abbreviations used in this paper: CL, chemiluminescence; ELAM- TNF is a pleotropic, proinflammatory cytokine with effects on a variety of cells. Many studies (1) (2) (3) (4) (5) (6) (7) (8) , including those on TNF receptor (TNFR)' (pS5) gene knockout mice (9) , have shown that TNF plays an important role in defense against infections. It stimulates and primes neutrophils for enhanced oxygen radical production (5, (10) (11) (12) (13) , degranulation (6, 11, 13) , and associated microbicidal and tumoricidal activities (1) (2) (3) (4) (5) (6) (7) . In malaria, phagocytic cell-mediated killing of the parasite constitutes a major part of the protective immunity against the asexual blood stages (6, (14) (15) (16) . We have previously shown that TNF and its structurally related lymphokine, lymphotoxin, enhance the human neutrophil-mediated killing of Plasmodium falciparum asexual intraerythrocytic stage (17, 18) and merozoites (19) . While TNF plays an important role in microbial immunity, it is also known to be a mediator of pathophysiology associated with a variety of infections and autoimmune inflammatory diseases ( 1, 2, 20, 21) . In P. falciparum infections, TNF is believed to play a crucial role in the pathogenesis of cerebral malaria (22) , which causes 20% mortality despite treatment with antimalarial drugs (23) . The toxic effects of the cytokine limit its application as a chemotherapeutic or immunoregulatory agent ( 1, 2, 24, 25) .
From a recently described region of the TNF molecule that possesses neutrophil-stimulatory properties (26) , it has been possible to derive a soluble 1 1-mer peptide that has high stability in serum. Characterization of its biological properties showed that the peptide primed neutrophils for enhanced killing of P. falciparum and significantly reduced the Plasmodium chabaudi parasitemia in mice. The peptide was found to prime neutrophils for increased release of oxygen-derived reactive species and degranulation, and it upregulated the expression of CR3 and FcyIII receptors. The action of the peptide appeared to be via the TNF receptors. In contrast to TNF, the synthetic peptide failed to promote the sequestration of P. falciparum schizonts and trophozoite-infected erythrocytes to human endothelial cells. Thus TNF(7080) appears to show substantial selectivity in inducing host-protective responses.
Methods
Peptide synthesis The peptide TNF (7, 80) , derived from the primary amino acid sequence of human TNF (see Fig. 1 ), was prepared by the F-moc-polyamine (27) method of solid phase peptide synthesis using the PepSyn KA solid resin (Cambridge Research Biochemical Ltd., Cambridge, United Kingdom) (28) . The sequence from the natural TNF was modified by substitution of isoleucine for leucine at position 76 (see Fig. 1 ). The modification extended the serum half-life of the peptide to > 90 min and increased water solubility (data not shown). A peptide, code 205, with the sequence H-Gly-Gly-Asp-Pro-Gly-ILe-Val-Thr-His-Ser-OH was used as a negative control. Fresh dilutions of the peptides were prepared daily in HBSS containing 0.1% human group AB heat-inactivated (56TC, 30 min) sera. These preparations contained < 0.1 LPS U/ ml as determined by the limulus amebocyte lysate assay.
Cytokines
Human recombinant TNF (99% purity) was produced by Genentech, Inc. (San Francisco, CA) and kindly provided by Dr. G. R. Adolf (ErnstBoehringer Ingelheim Institut, Vienna, Austria). This preparation had a specific activity of 6 x 107 U/mg assayed for cytotoxicity by the supplier on actinomycin-D-treated murine fibrosarcoma cell line L929. The preparation was > 98% pure, and LPS contamination was < 0.125 LPS U/ml (by limulus amebocyte lysate assay). Fresh dilutions of TNF were prepared daily in HBSS containing 0.1% heat-inactivated (560C, 30 min) human group AB sera. These preparations contained < 0.1 LPS U/mI.
Antibodies
The preparations of affinity-purified human anti-human TNFR mAb utr 1 (directed against human TNFR, p75) and mAb htr 9 (against human TNFR, p55) were provided by Dr. M. Brockhaus (Hoffman-La Roche, Ltd; Basel, Switzerland). TNF-neutralizing mAb (mAb 54) against human TNF was prepared as described previously (29) . The following mAbs were purchased: anti-human intercellular adhesion molecule 1 (ICAM-1) (Immunotech, Marseille, France), anti-human endothelial leukocyte adhesion molecule 1 (ELAM-1) (E-selectin) and vascular cell adhesion molecule 1 (VCAM-1) (Becton Dickinson and Co., San Jose, CA), and horseradish peroxidase-conjugated rabbit immunoglobulin (Dakopatts, Copenhagen, Denmark) anti-CD (18) . Three of the four isolates used possessed knobs. The experiments were conducted either with nonsynchronized cultures at 10' RBC/ml with 3-5% parasitemia (17, 18) or with purified trophozoite and schizont stages (31) .
Plasmodium chabaudi-infected mouse RBC stored under liquid N2 were used to initiate infections in mice. When the parasitemia reached -10%, blood was taken from the retroorbital plexus, washed once in normal saline (0.9% sodium chloride), adjusted to 2 x 106 RBC/ml, and used for in vivo studies.
Sera
Immune serum (IS) refers to serum or plasma obtained from individuals who were long-term residents in malaria-endemic areas in Papua New Guinea or the Solomon Islands. These sera contained high titers of anti-P. falciparum antibody and < 10 hemolytic units of complement (19 The percentage of mature parasites (A) was counted using Giemsastained thin smears prepared from the cultures (with known RBC number) at the beginning of the experiment. The number of HUVEC per well (B) was determined by adding 0.1% trypsin into the wells and counting the endothelial cells using a hemocytometer.
The number of IRBC adhered on 100 HUVEC = [(A) x (dpm due to adhered IRBC on HUVEC)] x 100/[(B) x (dpm of RBC)].
Effects ofpeptide TNF(7o-,) in P. chabaudi-infected mice 6-8-wk-old female BALB/c mice were infected with P. chabaudi (2 x 10' IRBC/mouse) intraperitoneally, and parasitemia was determined in blood smears daily. When the parasitemia reached 1%, the mice were randomly divided into three groups (five mice per group). Each group received 200 p1 of either TNF(7080) or control peptide (at 5 mg/kg body wt) or saline intraperitoneally daily for 4 consecutive d. Blood smears were taken daily for 8 d, and the mice were killed.
Blood smears were stained with Giemsa and examined at a magnification of 1,000. A minimum of 10,000 RBC were studied per mouse at a time, and the number of parasites found per 100 RBC was expressed as parasitemia.
Effects ofpeptide TNF (7oo8) and 7TNF in mice 
Chemiluminescence (CL) assay
The lucigenin and luminol-dependent CL assays were conducted as a measurement of the production of oxygen-derived reactive species as described previously (33) . Either peptide TNF(70-80) (0-01-100 Og), control peptide (0.01-100 jsg), or diluent was added to aliquots of PMN (106 in 100 p1 HBSS) in 2-ml vials and incubated at 37°C for 30 min in 5% CO2 in air. In a separate set of experiments, PMN were incubated with 100 j.d of HBSS containing mAb against TNF or TNF receptors before the addition of TNF, peptides, or diluent. At the end of the 30-min incubation period, 500 ILI of lucigenin (250 AM, final) or luminol (40 Og/ml, final) was added, and the final volume was adjusted to 1 ml. Where the priming effects for FMLP were studied, 100 ,1 of FMLP or HBSS was added before adjustment of the volume to 1 ml. The resulting light output was measured in a water-jacketed (37°C) luminometer (1251, Bio-Orbit Oy, Turku, Finland) and converted into millivolts using Multiuse software (1.08; Bio-Orbit Oy).
Degranulation PMN (107 in 200 /4 of HBSS) were pretreated with the peptides or diluent as described above, and the supernatants were saved for detection of vitamin B12-binding protein and /3-glucuronidase. The total respective enzyme content of PMN was obtained by incubating the same number of cells with 20 p1 of 10% Triton X-100 for 30 min in 1 ml of HBSS. The results were then expressed as percent release of total enzyme.
Vitamin B12-binding protein release was assayed as described previously (34) . Aliquots (100 p1) of PMN supernatants were incubated for 15 min at room temperature with 1 ml of HBSS containing 0.2% Triton X-100 and cyano-[57Co]cobalamine (100 I1, 0.05 yCi, 1.9 kBq).
At the end of the incubation, 2.5% (2 ml) aqueous charcoal solution was added, and the samples were centrifuged at 3,000 g for 10 min. Aliquots of the supernatants were counted in a gamma counter (1282 Compugamma; LKB-Wallac).
,/-Glucuronidase activity was determined fluorimetrically with 4-methylumbelliferyl-,3-D-glucuronide as substrate as described previously (35) , with the following modifications. Aliquots (50 p1) of PMN supernatants were incubated for 3 h at 37°C with 50 IL of 2.5 mM substrate in 0.1 M citric acid/sodium phosphate buffer (pH 4.5). and peptide preparations were heated at 800C for 30 min (which inactivates TNF and peptides but leaves the LPS activity intact) and compared with the nonheated cytokines. Experiments were also conducted in the presence of polymyxin-B (I ug/ml). The peptides and TNF were filtered through a positively charged filter (Zetapor filters; Cuno, Inc., Meriden, CT), and the filtrates were used in experiments. In addition, a TNFneutralizing mAb was used to ensure that the activity was due to the cytokine.
Statistical analysis
The results were compared by the two-tailed Student's t test.
Results

TNF (7080) -induced PMN priming for increased parasite killing
We have previously demonstrated that the PMN-activating properties of TNF were reflected in its ability to prime the phagocyte for increased killing of P. falciparum asexual blood stages (17, 18) . Therefore, the peptide TNF(7080) (Fig. 1) was examined for PMN priming in relation to this activity. PMN were pretreated with a range of concentrations of the peptide (2-100 11g/ 106 cells) and then mixed with P. falciparum and NS. The TNF(7S-O) peptide significantly enhanced the PMNmediated killing of P. falciparum over this dose range (Fig. 2) . Under the same conditions and identical dose range, the control peptide failed to enhance the antimalarial activity of PMN (Fig.  2) . The peptides had no direct effect on parasites.
The priming effects of TNF(7O8O) were evident also in the presence of immune serum containing anti-P. falciparum antibodies (Fig. 3) 
Mechanisms of TNF(7o8o) -induced priming
Previously it has been demonstrated that the TNF-induced priming of increased antimicrobial activity of PMN is associated with an increased expression of integrin and Fcy receptors, increased generation of oxygen-derived reactive species, and increased degranulation response (for review, see reference 6).
We therefore proceeded to characterize the TNF(7o8o) properties in relation to the above activities. Primingfor increased respiratory burst and degranulation. To simplify the assessment of TNF(70-80)-induced priming, we examined the priming effect for the agonist FMLP. Lucigenindependent chemiluminescence assay was used as a measure 4). A similar trend was also seen for luminol-dependent PMN chemiluminescence response (data not presented). Fig. 5 shows a comparison between TNF (100 U) and TNF(7,O80) (0.01 Mg/ ml). Both significantly stimulated (P < 0.001) PMN for lucigenin-enhanced chemiluminescence response and also primed (P < 0.001) the cells to FMLP.
Degranulation was measured as the release of ,6-glucuronidase and vitamin B-12-binding protein, which are markers of specific and azurophilic granules, respectively. While TNF(7080) induced only a small and nonsignificant release of /3-glucuronidase (Fig. 5 A) , it still primed for an increased release (P < 0.01) of this enzyme, in response to FMLP (Fig.   5 A) . TNF(7080) induced a direct degranulation response, increasing the basal vitamin B12-binding protein (14.5±1.5) by 2.8-fold (P < 0.001), with a further 3.1-fold increase with FMLP ( Fig. 5 B) (P < 0.001).
Modulation of surface expression of integrin and Fc receptor expression. This was assessed by flow cytometry using mAb.
Pretreatment of PMN with TNF(7080) significantly (P < 0.01 ) increased the expression of CD18, the common (-chain of the integrin receptors (Fig. 6 A) . When the expression of the achains (CD1 1a, CD1 lb, and CD1 1c) was examined, TNF(70-80) induced a significant (P < 0.05) increase in expression of CD11b (Fig. 6 B) but not CD11a or CDI1c (data not presented).
Treatment of PMN with TNF(70o90) caused a significant (P < 0.05) increase in the FcRylI1 expression (Fig. 6 C) but no significant increase in expression of FcR-yH (data not presented).
Interaction of TNF(7o-,o) with TNF receptors. The effects of TNF(70o80) are most likely mediated via the TNF receptors. We attempted to investigate this possibility by making a modified TNF(70o80) containing a tyrosine that could be iodinated as the carboxy-terminal amino acid for receptor binding studies. However, the modified peptide did not stimulate the PMN respiratory burst and failed to associate with PMN in binding assays. Therefore, an alternative approach was used to determine whether or not TNF(70o80) binds to the TNF receptor.
Anti-TNF monoclonal antibody (mAb54) that neutralized the activity of TNF was examined for ability to inhibit the peptide-induced respiratory response. The peptide-induced lucigenin-dependent chemiluminescence response was inhibited by mAb54 (Fig. 7 A) . In a second set of experiments, the peptide was treated with mAb against either the p75 (utr 1) or p55 (htr 9) TNF receptors (at 10 /g/ml). The results showed that both antibodies inhibited the ability of TNF(7O8O) peptide to stimulate lucigenin-dependent CL response in PMN (Fig. 7 B) .
Effect of TNF(7o-8o) on endothelial cell adhesion function A major pathophysiology-inducing characteristic of TNF is its ability to increase the adhesive properties of the endothelium.
We therefore compared the ability of TNF and TNF(70-80) pep- tide to alter the expression of adhesion molecules on endothelial cells and their ability to increase adhesion of IRBC to the endothelial cells.
Expression ofELAM-J, ICAM-1, and VCAM-J. The expression of three adhesion molecules on endothelial cells was studied after pretreatment with either TNF, TNF(7080), or diluent. The data presented in Fig. 9 show that expression of all three adhesion molecules is increased by TNF (P < 0.001). In contrast, TNF(7)80) did not increase their expression (Fig. 8) (Fig. 9 A) or a radiometric assay (Fig. 9 B) . The results showed that TNF significantly enhanced (P < 0.05) the adherence of IRBC to HUVEC (Fig. 9) . In contrast, when endothelial cells were pretreated with TNF(7080), no increase of IRBC adherence was evident (Fig. 9) . Morphological observations confirmed that the addition of the peptides or TNF to In cerebral malaria, TNF is implicated in the pathology associated with the sequestration of IRBC in the microvasculature of vital organs such as the brain and lungs (22) . The results of the present study reemphasize the findings by showing that TNF promotes enhancement of IRBC adherence to cultured endothelial cells. One of the differences observed between TNF(70 80) and TNF was the failure of the peptide to promote adhesion of IRBC to HUVEC. This is consistent with our findings that TNF(70o80) did not increase the expression of ICAM-1, ELAM-1, and VCAM-1 on HUVEC. These molecules are thought to be involved in the adherence of IRBC to endothelial cells (39, 40) . Our results showed that, unlike TNF, peptide TNF(70O80) did not promote parasite sequestration, and in fact inhibited the effects of TNF on endothelial cells that lead to enhanced IRBC adhesion. When the endothelial cells were exposed to both TNF and the peptide simultaneously, the peptide inhibited the ability of TNF to enhance IRBC adhesion, presumably because the peptide is competing for the TNF receptors. Since much of the pathology due to P. falciparum infection occurs as a consequence of IRBC sequestration to host endothelium, the peptide can be considered to be devoid of this component of the pathophysiology. It is also possible that certain functions of TNF require the trimer form of TNF (e.g., expression of ELAM, ICAM, and VCAM on endothelial cells and direct tumor toxicity), while for other activities (e.g., activation and priming of PMN) trimer formation may not be essential. Attempts to explain these biological differences could hence be evaluated by engineering a trimer of the peptide with spacers between the active sequences and determining whether the normal TNF activity is regained. 
